Treatment Optimization and Nephrolithiasis Recurrence Prevention With Interdisciplinary Care

Study on Treatment Optimization and Nephrolithiasis Recurrence Prevention With Interdisciplinary Care

Nearly 10% of the Belgian population suffer from kidney stone disease. Recent reviews reported that kidney stones represent an underestimated risk factor for further kidney function deterioration. Preventive measures are recommended in lithiases patients to prevent the formation of new stones. The individual effects of different medicated prosthetic interventions have been documented in clinical trials. However, there is little data on the effectiveness of combining these different preventive measures in routine clinical practice (real-world context).

Patients with kidney stone disease require a complete metabolic assessment. The three main factors contributing to the stone's formation are the patient's metabolism, diet and lifestyle. Metabolic work-up is recommended by the American Urology Association to identify and correct the factors responsible for urinary stone formation such as hypercalciuria, hyperoxaluria, hyperuricuria, hypocitraturia or abnormalities of urinary pH. The metabolic work-up includes at minimum the 24h urine test, a blood test and spot urine test. Dietary habits and lifestyle are assessed by means of a questionnaire.

The CHU Brugmann Hospital has a specialized multidisciplinary clinic for renal lithiases and mineral metabolism. Preventive personalized and interdisciplinary care in CHU Brugmann consists of a full metabolic work-up allowing the identification of lithogenic risk factors by nephrologists, dietary assessment by specialized dieticians and specific treatment protocol associated with regular follow-up.

The aim of this study is to evaluate, in the context of a retrospective single-center cohort study, the effect of preventive personalized and interdisciplinary care on the evolution of all urinary lithogenic risk factors and the recurrence of kidney stones (rate of renal colics, emergency room admissions, and urological interventions).

Study Overview

• Status: Recruiting
• Conditions: Kidney Stone

• Study Type: Observational
• Enrollment (Estimated): 164

Contacts and Locations

• Study Contact: Name: Sirika Chhem; Phone Number: 024772641; Email: Sirika.Chhem@ulb.be
• Study Contact Backup: Name: Agnieszka POZDZIK; Phone Number: 024752639; Email: Agnieszka.POZDZIK@chu-brugmann.be

Study Locations

• Belgium
  • Brussels, Belgium, 1020
    • Recruiting
    • CHU Brugmann
    • Contact: Agnieszka POZDZIK; Phone Number: 024772641; Email: Agnieszka.POZDZIK@chu-brugmann.be
    • Principal Investigator: Sirika Chhem

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients of the CHU Brugmann Hospital who fulfill the criteria of active or past history of kidney stone, from 01/01/2018 till 31/10/2023

Description

Inclusion Criteria:

• All patients of the CHU Brugmann Hospital who fulfill the criteria of active or past history of kidney stone, from 01/01/2018 till 31/10/2023
• Minimum follow-up time of 2 months with biochemical and clinical results available

Exclusion Criteria:

- None

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of acute renal colics	Number of acute renal colics	From first patient consultation till 31/10/2023
Number of emergency admissions	Number of emergency admissions	From first patient consultation till 31/10/2023
Number of surgeries	Number of surgeries	From first patient consultation till 31/10/2023
Number of hospitalizations	Number of hospitalizations	From first patient consultation till 31/10/2023
Identified genetics abnormalities	List of identified genetics abnormalities	From first patient consultation till 31/10/2023
Wisconsin questionnaire	Changes in the quality of life in the patients (evolution of the scoring of the Wisconsin questionnaire)	From first patient consultation till 31/10/2023
Kidney function outcome	Kidney function outcome	Status at 31/10/2023

Collaborators and Investigators

• Sponsor: Agnieszka Pozdzik

Study record dates

Study Major Dates

• Study Start (Actual): December 12, 2023
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: April 11, 2024
• First Submitted That Met QC Criteria: April 11, 2024
• First Posted (Actual): April 16, 2024

Study Record Updates

• Last Update Posted (Actual): April 16, 2024
• Last Update Submitted That Met QC Criteria: April 11, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Kidney Diseases; Urologic Diseases; Disease Attributes; Pathological Conditions, Anatomical; Urolithiasis; Urinary Calculi; Calculi; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Recurrence; Kidney Calculi; Nephrolithiasis
• Other Study ID Numbers: STONECARE

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No